#USA #San Diego #ALS #Amydis #TDP-43

A New Frontier in ALS Detection: Amydis and the Power of Eye Imaging

Amydis Inc., a clinical-stage company based in San Diego, is making strides in the detection of a critical biomarker associated with neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). The company recently announced that it has been awarded a Phase 2 grant of $2.5 million from the National Institute of Aging, National Institutes of Health (NIH). This funding will support Amydis’ innovative approach using ocular tracers to identify TDP-43, a protein whose aggregation is a hallmark of several neurodegenerative conditions.

Why TDP-43 Matters

Studies indicate that approximately 97% of ALS patients exhibit TDP-43 pathology. However, the current diagnostic methodologies are lacking; there are no blood tests or brain imaging techniques that can directly identify TDP-43 in living patients. Consequently, diagnosing ALS often involves a prolonged process of exclusion, where patients wait months or even years to receive an accurate diagnosis. This delay can severely impact both treatment options and the overall quality of life for patients and their families.

Redefining Diagnosis with Ocular Tracers

To combat this pressing issue, Amydis has developed a non-invasive, fluorescent ocular tracer. This innovative technology acts as a simple eye test to detect TDP-43 using conventional ophthalmic imaging techniques. Given that many patients routinely visit eye care professionals for vision changes, this method offers a valuable opportunity to incorporate molecular biomarker detection directly into standard clinical practice.

Dr. Stella Sarraf, the Founder and CEO of Amydis, articulates the urgency of this development: "For patients and families facing ALS and related dementias, time is everything. We believe the eye represents a new frontier in neurodegenerative disease detection. Earlier detection has the potential to change how ALS and related diseases are diagnosed, studied, and ultimately treated."

Building on Phase 1 Success

The backing from NIH follows a successful Phase 1 grant, during which Amydis proved that its ocular tracer could detect TDP-43 deposits in the retinal cadaver tissues of individuals with ALS, frontotemporal dementia (FTD), and Limbic-predominant Age-related TDP-43 Encephalopathy (LATE). This foundational work was made possible through invaluable support from collaborative partners including Georgetown University and Mass General Brigham.

The findings from this Phase 1 grant were recently presented at notable conferences, including the NEALS conference and the International Symposium on MND/ALS, marking a significant milestone in ALS research. As a next step, the Phase 2 grant will enable further analysis of retinal tissues to map TDP-43 deposits and apply artificial intelligence to discern disease-specific patterns.

Precision Medicine and Future Implications

Dr. Merit Cudkowicz, Executive Director of the Mass General Brigham Neuroscience Institute, emphasizes the significance of such advancements: "Prodromal detection of TDP-43 in people with ALS would be a step forward for our field. A molecular biomarker test to detect TDP43 in the eye has the potential to facilitate clinical trial design and drug targeting, as well as accelerate patient enrollment in clinical trials."

Overall, Amydis is not just developing a test; they are aiming to reshape the clinical landscape for neurodegenerative diseases. By utilizing the eye as a window into neurology, the company hopes to leverage its innovations for early diagnostics, paving the way for precision treatments that could ultimately improve patient outcomes. This represents a significant step in transforming how these disorders are detected and treated, offering new hope to patients and families alike.

About Amydis

Amydis is dedicated to advancing early disease detection through affordable and non-invasive ocular technologies. The company is focused on developing proprietary ocular tracers that enable the identification of molecular biomarkers for various diseases impacting the eye, heart, and brain. Amydis is actively creating a data warehouse for multi-omics analysis, with the ultimate aim of empowering AI-driven health insights and facilitating quicker and more accurate diagnoses in a clinical setting.

For more information, visit Amydis.